Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Next Previous
Trial Profile

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Afatinib (Primary) ; Atezolizumab (Primary) ; Cetuximab (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Everolimus (Primary) ; Gemcitabine (Primary) ; Ipilimumab (Primary) ; Larotrectinib (Primary) ; Niraparib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Regorafenib (Primary) ; Sunitinib (Primary) ; Talazoparib (Primary) ; Temsirolimus (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary) ; Vemurafenib (Primary)
  • Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; B-cell lymphoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus Therapeutic Use
  • Acronyms TAPUR

    • Most Recent Events

    • 20 Jan 2024 Results (n=10) assessing effect of Talazoparib in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations, presented at the 2024 Gastrointestinal Cancers Symposium
    • 20 Jan 2024 Results(n=10) in a cohort of pts with EC with CDKN2A loss or mut treated with abemaciclib , presented at the 2024 Gastrointestinal Cancers Symposium
    • 24 Oct 2023 Results from 2 cohorts of patients with solid tumors with CDK4 or CDK6 amp treated with Palbociclib presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top